You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Mesothelin

Showing 1 - 25 of 133
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Mesothelin-positive Advanced Malignant Solid Tumors Trial in Hangzhou (UCLM802 Cell Injection (Anti-mesothelin CAR-T cells))

Recruiting
  • Mesothelin-positive Advanced Malignant Solid Tumors
  • UCLM802 Cell Injection (Anti-mesothelin CAR-T cells)
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital Zhejiang University School of Medi
May 11, 2023

Mesothelin-positive Advanced Malignant Solid Tumors Trial (Anti-mesothelin CAR-T cells)

Not yet recruiting
  • Mesothelin-positive Advanced Malignant Solid Tumors
  • Anti-mesothelin CAR-T cells
  • (no location specified)
Mar 13, 2023

Solid Tumor Trial (UCLM802 Cell Injection)

Not yet recruiting
  • Solid Tumor
  • UCLM802 Cell Injection
  • (no location specified)
Mar 7, 2023

Pancreas Cancer, CAR-T Cell Therapy, Mesothelin Trial in Guangzhou (CAR-T cells)

Recruiting
  • Pancreas Cancer
  • +3 more
  • CAR-T cells
  • Guangzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Mar 10, 2023

Breast Cancer Trial in Philadelphia (huCART-meso cells, Mesothelin Expression Testing)

Not yet recruiting
  • Breast Cancer
  • huCART-meso cells
  • Mesothelin Expression Testing
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Jan 5, 2023

Ovarian Cancer, Cholangiocarcinoma Recurrent, Mesothelioma, Malignant Trial (SynKIR-110, Autologous T cells Transduced with

Not yet recruiting
  • Ovarian Cancer
  • +2 more
  • SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR
  • (no location specified)
Oct 5, 2022

Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 Trial in Seattle (Autologous Mesothelin-specific

Recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Stage IV Pancreatic Cancer AJCC v8
  • Autologous Mesothelin-specific TCR-T Cells
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 31, 2023

Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe), Epithelial Tumors, Malignant Trial run by the National

Not yet recruiting
  • Malignant Pleural Mesotheliomas (Mpm)
  • +4 more
  • Cytoreductive surgery
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Pancreatic Cancer Trial in Shatin (MSLN CART)

Not yet recruiting
  • Pancreatic Cancer
  • MSLN CART
  • Shatin, N.t., Hong Kong
    Endoscopy Centre, Prince of Wales Hospital
Sep 19, 2023

Ovarian Cancer Trial in Hangzhou (mesothelin-specific chimeric antigen receptor T cell injection)

Recruiting
  • Ovarian Cancer
  • mesothelin-specific chimeric antigen receptor T cell injection
  • Hangzhou, China
    First affiliated hospital, School of Medicine, Zhejiang Universi
May 12, 2022

Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer Trial in Paris, Rennes, Milano

Recruiting
  • Epithelial Ovarian Cancer
  • +2 more
  • NI-1801
  • Paris, France
  • +4 more
Nov 4, 2022

Lung Adenocarcinoma, Ovarian Cancer, Peritoneal Carcinoma Trial in Philadelphia (huCART-meso cells)

Recruiting
  • Lung Adenocarcinoma
  • +5 more
  • huCART-meso cells
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Dec 1, 2022

Lung Cancer, Non Small Cell Lung Cancer, Adenocarcinoma of Lung Trial run by the National Cancer Institute (NCI) (LMB-100,

Active, not recruiting
  • Lung Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Oct 4, 2022

Tumors, Pancreatic Tumors Trial run by the NCI (LMB-100, Nab-Paclitaxel, Mesothelin Expression)

Completed
Has Results
  • Neoplasms
  • Pancreatic Neoplasms
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 16, 2022

Tumors With Mesothelin Expression, Epithelioid Mesothelioma, Cholangiocarcinoma, Extrahepatic Trial run by the NCI (LMB-100,

Active, not recruiting
Has Results
  • Neoplasms With Mesothelin Expression
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 18, 2022

Mesothelioma Trial run by the National Cancer Institute (NCI) (LMB-100, nab-paclitaxel)

Completed
Has Results
  • Mesothelioma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 28, 2022

Mesothelioma Trial run by the National Cancer Institute (NCI) (LMB-100, ipilimumab)

Recruiting
  • Mesothelioma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 6, 2022

Clinical Management of Esophageal Adenocarcinoma (EAC)

Active, not recruiting
  • Esophageal Cancer
  • Adenocarcinoma
  • serum and tissue mesothelin
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Oct 1, 2021

Advanced Cancers Associated With Mesothelin Expression Trial in United States (HPN536)

Active, not recruiting
  • Advanced Cancers Associated With Mesothelin Expression
  • HPN536
  • Phoenix, Arizona
  • +15 more
Sep 9, 2022

Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant Trial in Bethesda, Nashville (TC-510, Fludarabine,

Recruiting
  • Mesothelioma
  • +14 more
  • TC-510
  • +2 more
  • Nashville, Tennessee
    Sarah Cannon Research Institute
Jul 14, 2022

Mesothelioma Trial run by the NCI (LMB-100, Pembrolizumab)

Terminated
Has Results
  • Mesothelioma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Nov 3, 2021

Pancreatic Cancer Trial in New Haven, New Brunswick, Nashville (anetumab ravtansine)

Completed
Has Results
  • Pancreatic Cancer
  • anetumab ravtansine
  • New Haven, Connecticut
  • +2 more
Oct 11, 2021

Malignant Pleural Disease, Mesothelioma, Metastases Trial in United States (iCasp9M28z T cell infusions, cyclophosphamide,

Active, not recruiting
  • Malignant Pleural Disease
  • +4 more
  • iCasp9M28z T cell infusions
  • +2 more
  • Basking Ridge, New Jersey
  • +5 more
Nov 14, 2022

Lung Cancer, Cancer, Immunotherapy Trial in Guangzhou (CAR-T cells targeting PSCA, MUC1, TGFß, HER2, Mesothelin, Lewis-Y, GPC3,

Recruiting
  • Lung Cancer
  • +3 more
  • CAR-T cells targeting PSCA, MUC1, TGFβ, HER2, Mesothelin, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2, or B7-H3
  • Guangzhou, Guangdong, China
  • +1 more
Nov 26, 2021

Refractory Malignant Solid Tumor Trial in Shanghai (anti-MESO CAR T cells)

Recruiting
  • Refractory Malignant Solid Neoplasm
  • anti-MESO CAR T cells
  • Shanghai, China
    Department of Oncology, Ruijin Hospital
Sep 16, 2021